CalAmp (CAMP) slipped to a loss in the second quarter from a profit last year due to a charge for the early retirement of debt. The results surpassed analysts’ expectations and the wireless communications company guided third-quarter in line with consensus. Following this, the stock rose over 2% in the after hours.
Net loss for the quarter was $0.85 million or $0.02 per share compared to a profit of $12.23 million or $0.34 per share a year ago, which included a $15 million gain on the legal settlement. Adjusted earnings increased 15% to $0.31 per share.
Revenue grew 7% to $96 million. Telematics Systems revenue increased by 4.1% year-over-year driven by strong growth in Network and OEM products revenue. Software & Subscription Services revenue jumped by 21% on its freight transport subscriber additions and its LoJack Italia business.
Looking ahead into the third quarter, CalAmp expects revenue in the range of $94 million to $99 million and adjusted EPS in the range of $0.29 to $0.35. GAAP earnings are anticipated to be in the range of $0.07 to $0.13 per share. Adjusted EBITDA is predicted to be $12 million to $16 million. The forecast includes the expected gain of about $2.5 million related to the legal settlement with a former LoJack supplier.
The company completed a $230 million convertible debt issuance with a portion of the proceeds or about $54 million used to repurchase outstanding convertible notes due in May 2020 and another $15 million used to repurchase outstanding common stock.
Shares of CalAmp ended Thursday’s regular session down 1.20% at $22.28 on the Nasdaq.
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company